Literature DB >> 22362121

The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation.

Gülsan Türköz Sucak1, Demet Gökalp Yaşar, Zeynep Arzu Yegin, Mehmet Ali Ergün, Zübeyde Nur Ozkurt, Şahika Zeynep Aki, Sezen Güntekin.   

Abstract

Iron overload is considered as a significant cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. The presence of hemochromatosis gene (HFE) mutations might exacerbate iron toxicity in the post-transplant setting. This prospective study was planned to evaluate the genetic spectrum of HFE mutations in Turkish patients undergoing HSCT and the impact of HFE genotype on transplant morbidity and mortality. HFE genotypes of 102 patients [median age, 27.5 years (16-64 years); male/female, 73:29], who underwent allogeneic HSCT, were analyzed. Twenty-two patients were heterozygous and 1 patient was homozygous for the H63D mutation, while the C282Y mutation was observed in none of our patients. The frequency of invasive fungal infections (IFI) was significantly higher in H63D-mutated patients (p=0.004). H63D mutation was identified as an independent risk factor for the development of IFI (p=0.006, OR=0.554, SE=0.208), without an impact on overall survival and transplant-related mortality. The multifactorial iron-overloaded state in HSCT recipients might affect the phenotypic expression of HFE mutations and alter the severity of clinical presentation. The impact of HFE genotype on iron parameters and transplant-related morbidity and mortality should be validated with further studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362121     DOI: 10.1007/s00277-012-1428-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  1 in total

Review 1.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.